Saturday, June 15, 2019 7:15:05 PM
Sentiment,
17 patients were enrolled before the restart in May 3, 2011.
See enrollment curve: 5.1% of 331= 17 patients enrolled between June 2008 and March 2009.
https://investorshub.advfn.com/uimage/uploads/2018/9/22/wnnwsScreen_Shot_2018-09-22_at_8.38.11_AM.png
And listen to Dr.Marnix Bosch ASCO 2017:
"We only recruited up to 20 patients."
Min.12.00
But 3 of these patients are not in the Main Arm. Form 8-K February 8, 2017.
They redesigned the study as a randomized, placebo controlled, double blinded study with a cross-over arm allowing control patients to be treated with DCVax-L in the event that their cancer progresses.
http://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=11831872-871-4777&type=sect&TabIndex=2&companyid=89350&ppu=%252fdefault.aspx%253fsym%253dNWBO
NWBO SEC FORM 10K YEAR 2007 (April 8, 2008):
http://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=5866529-857-533968&type=sect&TabIndex=2&companyid=89350&ppu=%252fdefault.aspx%253fsym%253dNWBO
SEC statements tell us where enrollment stands near the end of 2008, which was shortly before the study stopped:
NWBO SEC FORM 10-Q the quarterly period ending Sept 30, 2008
(Dated: November 19, 2008).
http://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=6261653-857-253287&type=sect&TabIndex=2&companyid=89350&ppu=%252fdefault.aspx%253fsym%253dNWBO
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM